HANSHOW
7.6.2024 10:31:31 CEST | Business Wire | Press release
Hanshow, a leader in Electronic Shelf Labels (ESLs) and digital retail solutions, and Leroy Merlin, a global DIY leader, have partnered to enhance customer and employee experiences by deploying ESLs across over 50,000 products integrated with the Leroy Merlin mobile app in France. Customers now enjoy seamless shopping with easy product geolocation and personalized recommendations in Leroy Merlin stores. After 18 months of R&D, they implemented a fully customized solution in all Leroy Merlin outlets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604438443/en/
Hanshow's ESL Solution at Leroy Merlin. (Graphic: Business Wire)
Enhanced Customer Support with Leroy Merlin's Mobile Application
This immersive experience is powered by the Leroy Merlin mobile application in conjunction with Hanshow's state-of-the-art ESL solutions. Leroy Merlin’s integration of Hanshow ESL into its app offers geolocation in-store to guide customers to products and aisles. This enhances the shopping experience and allows staff to provide more personalized advice and support.
The ESL solution also provides price consistency between online and offline channels, enriching user experience with various features such as customer reviews, enriched product descriptions, access the Home Index to assess a product's environmental and social impact, and the ability to flash labels directly from the application. These functions provide flexibility for consumers and store associates.
"We have successfully met the expectations of Leroy Merlin customers by developing a solution that enhances the in-store experience. By combining data and technological innovations, we have created a tailor-made tool that delivers a personalized experience for each customer," explains Pierre Fosseux, VP of Hanshow France.
Enhancing Retail Efficiency and Customer Experience
Whether it's stock management, restocking, or click-and-collect order preparation, the geolocation of products in the shop is a real time-saver for staff, who can devote themselves to focusing on higher-value tasks. "It now takes sales staff around 75 seconds to pick up a product, instead of 90 seconds previously, for orders placed online and picked up in the shop within a two-hour window chosen by the customer," says Olivier Personne, Merchandising Optimization Manager at Leroy Merlin. Eliminating price differences has positively improved customer satisfaction.
"The solution co-constructed with Hanshow enriches the customer experience across online and offline channels while simplifying in-store team tasks. Currently deployed in France, it is designed for larger-scale rollout in other Leroy Merlin locations," explains Hugues Hartung de la Roer, Concept & Merchandising Director at Leroy Merlin France.
Exemplifying both companies' commitment to enhancing customer satisfaction and driving innovation in the retail sector, the new solution not only simplifies the shopping process but also provides valuable data insights to improve store operations and customer engagement.
The collaboration won the Reta Awards 2024: Best In-store Solution for Leroy Merlin and Top Supplier for Hanshow, for transforming the retail environment with advanced technology.
About Leroy Merlin France
A pioneering company in the Adeo Group, Leroy Merlin is now the leading brand in France in all distribution channels for improving the home and the living environment. Specialising in the sale of products, projects and services, Leroy Merlin France has set itself the goal of building new ways of living with everyone, so that we can live better in the future, and puts customer satisfaction at the heart of its business.
About Hanshow
Hanshow is one of the global leaders in the development and manufacturing of electronic shelf labels and digital store solutions . The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across more than 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604438443/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom